Acrux in dire need of booster shot

Acrux suffered its worst sell-off in 14 months on a disappointing sales update on its flagship testosterone treatment drug.

Acrux (ACR) suffered its worst sell-off in 14 months on a disappointing sales update on its flagship testosterone treatment drug.

The stock crashed 12.5% to its lowest level this calendar year of $2.74 at 10.30 AEST when management warned that growth in the global testosterone market continues to slow and market share for its drug Axiron, which is exclusively distributed by Eli Lilly, is flattening.

The potential bad news was flagged in our article yesterday, although it has come a little sooner than we had anticipated. Investors will be keen on hearing what other growth plans the company has at its AGM on November 21.

Eli Lilly reported sales of Axiron came in at $US40.6 million in the September quarter compared with $US47.1 million in the previous quarter.

The fact that Eli Lilly will pay Acrux $US25 million as milestone payment provides little comfort for investors.

Acrux is the worst performer in the Uncapped 100 this morning.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles